KBC Group
PTCT icon

KBC Group’s PTC Therapeutics PTCT Stock Holding History

KBC Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191K Hold
2,347
– – ﹤0.01% 1066
2026
Q1 		$160K Hold
2,347
– – ﹤0.01% 1063
2025
Q4 		$178K Hold
2,347
– – ﹤0.01% 965
2025
Q3 		$144K Hold
2,347
– – ﹤0.01% 1058
2025
Q2 		$115K Sell
2,347
-724
-24% -$34.4K ﹤0.01% 1115
2025
Q1 		$156K Buy
3,071
+26
+0.9% +$1.3K ﹤0.01% 1217
2024
Q4 		$137K Buy
3,045
+813
+36% +$34.8K ﹤0.01% 1350
2024
Q3 		$83K Buy
2,232
+504
+29% +$16.9K ﹤0.01% 1416
2024
Q2 		$53K Sell
1,728
-442
-20% -$14.3K ﹤0.01% 1583
2024
Q1 		$63K Buy
2,170
+619
+40% +$17.3K ﹤0.01% 1410
2023
Q4 		$43K Hold
1,551
– – ﹤0.01% 1634
2023
Q3 		$35K Buy
+1,551
New +$57.7K ﹤0.01% 1714

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

KBC Group's PTCT Position: Q2 2026 in Review

KBC Group held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 2,347 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

KBC Group first reported a position in PTCT in Q3 2023 and has held it in 12 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • KBC Group held 2,347 shares of PTC Therapeutics worth $191K as of Q2 2026.
  • KBC Group left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1066 holding.
  • KBC Group first reported a position in PTC Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.